Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Alpha-Lipoic Acid (ALA) is an antioxidant that has been studied for a variety of neurological and metabolic conditions. Regarding migraines, there is some emerging scientific evidence suggesting a potential benefit, though the data are still limited and not robust enough for strong clinical recommendations. A few small randomized controlled trials have evaluated the efficacy of ALA in migraine prophylaxis. For example, a double-blind, placebo-controlled study published in 2007 found that supplementation with ALA (600 mg/day) for three months significantly reduced the frequency and severity of migraine attacks compared to placebo. Another trial indicated that ALA could improve endothelial function, which is thought to play a role in migraine pathophysiology.

The suggested mechanisms include ALA’s antioxidant properties, improvement of mitochondrial function, and enhancement of nitric oxide-mediated vasodilation, all of which may be relevant since oxidative stress and vascular dysfunction are implicated in migraine pathogenesis. However, these studies are generally small in size and of short duration, and larger, more rigorous trials are needed to confirm these findings.

In summary, while there is some scientific evidence supporting the use of Alpha-Lipoic Acid for migraine prevention, it is preliminary, and ALA should not be considered a first-line therapy. The strength of evidence is moderate at best, justifying a rating of 2 on a 0-5 scale.

More about Alpha-Lipoic Acid
More about Migraine

Other ingredients used for Migraine

Other health conditions supported by Alpha-Lipoic Acid

Products containing Alpha-Lipoic Acid